CD19 and B-cell non-Hodgkin lymphoma: Okamoto et al. reported that individuals with hematological malignancy, especially B-cell lymphoma, tend to have lower immunological response to COVID-19 vaccines even after 1 year of completing immunotherapy and/or chemotherapy, and that the amount of CD19+ lymphocytes is crucial for developing antibodies [27].